Table 1. Categorization of studies on epidemiological, microbiological and prevention aspects.
|
|
Relevance for inclusion | Results and conclusions |
---|---|---|---|
|
|
Epidemiological, clinical, death and vaccination aspects | Increased incidence of pertussis and its complications |
|
|
Review of clinical, microbiological and epidemiological aspects | Important disease in public health and reemergence in the 21st century |
|
|
Review of clinical aspects, prevention and control | Epidemiological changes in infection and new prevention strategies |
|
|
Review of epidemiological, clinical and molecular biology aspects | Broad subject review, including other species of Bordetella |
|
|
Clinical, laboratory and radiological predictors for pertussis | Cyanosis and lymphocytosis were independent predictors of pertussis in children up to six months of age |
|
|
Virulence factors and prevention strategies | Host-toxin interaction defines immunological vaccine modulation by natural infection |
|
|
Review of clinical picture and prevention | Approach to disease improved over the past 50 years |
|
|
Official protocol, with changes in definitions and criteria | Redefines case criteria and recommends preferential use of azithromycin |
|
|
Official protocol, in use in Brazil | Update of concepts, case criteria and therapeutic recommendations |
|
|
Pertussis in children and adolescents: diagnosis, treatment and prevention | Adolescents and adults and their importance in the chain of transmission. Recommends their immunization |
|
|
Duration of vaccine immunity | Immunity conferred by DTP is longer lasting than DTPa |
|
|
Implantation of the dTpa vaccine | Criteria and recommendations for use of the dTpa vaccine in adults |
|
|
Prevention strategies | Recommendation of vaccination of the pregnant woman with dTpa |
|
|
Analysis of the epidemiological situation of pertussis in Brazil, 2015 | Epidemiological standard would not have changed in Brazil, continuing to undertake preferentially infants under the age of one. |
|
|
Analysis of the epidemiological situation of pertussis in Brazil, 2010-2014 | Increased number of cases in Brazil due to cyclical behavior of the disease |
|
|
Virulence Factors | Detailed description of the virulence mechanisms |
|
|
Virulence mechanisms | Detailed description of toxins, including molecular biology |
CGPNI: General Coordination of the National Immunization Program; SVS: Secretariat of Health Surveillance; MS: Ministry of Health; DTP:triple-cell whole-cell bacterial vaccine against diphtheria, pertussis and tetanus; DTPa: diphtheria, tetanus, and pertussis adsorbed vaccine; dTpa:triple acellular bacterial for use in adolescents and adults; CDC: Centers for Disease Control and Prevention.